Immix Biopharma (IMMX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 22, 2026, to elect nine directors and ratify Crowe LLP as auditor for 2026.

• Record date for voting is March 31, 2026, with 53,012,092 shares outstanding.

• Proxy materials are available online, with options for electronic or paper delivery.

• Voting can be done online, by mail, or in person; proxies are revocable.

Voting matters and shareholder proposals

• Proposals include electing nine director nominees and ratifying Crowe LLP as independent auditor.

• Directors are elected by plurality; auditor ratification requires a majority of votes cast.

• Board recommends voting FOR all director nominees and FOR auditor ratification.

• Shareholder proposals for the 2027 meeting are due by December 7, 2026, for proxy inclusion.

Board of directors and corporate governance

• Board consists of nine directors, six of whom are independent under Nasdaq rules.

• CEO Ilya Rachman serves as Chairman; Helen Adams is lead independent director.

• Three standing committees: Audit, Compensation, and Corporate Governance/Nominating, all with independent members.

• Board and committees met regularly in 2025; all directors attended at least 75% of meetings.

• Board diversity is valued, though no formal diversity policy is adopted.